Logo image of KPTI

KARYOPHARM THERAPEUTICS INC (KPTI) Stock Fundamental Analysis

NASDAQ:KPTI - Nasdaq - US48576U2050 - Common Stock - Currency: USD

4.2  -0.33 (-7.28%)

After market: 4.3 +0.1 (+2.38%)

Fundamental Rating

2

KPTI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. KPTI has a bad profitability rating. Also its financial health evaluation is rather negative. KPTI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KPTI had negative earnings in the past year.
KPTI had a negative operating cash flow in the past year.
KPTI had negative earnings in each of the past 5 years.
KPTI had a negative operating cash flow in each of the past 5 years.
KPTI Yearly Net Income VS EBIT VS OCF VS FCFKPTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

KPTI has a Return On Assets (-48.96%) which is in line with its industry peers.
Industry RankSector Rank
ROA -48.96%
ROE N/A
ROIC N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KPTI Yearly ROA, ROE, ROICKPTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

KPTI has a better Gross Margin (96.20%) than 95.54% of its industry peers.
In the last couple of years the Gross Margin of KPTI has remained more or less at the same level.
KPTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
KPTI Yearly Profit, Operating, Gross MarginsKPTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

1

2. Health

2.1 Basic Checks

KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KPTI has been increased compared to 1 year ago.
Compared to 5 years ago, KPTI has more shares outstanding
The debt/assets ratio for KPTI is higher compared to a year ago.
KPTI Yearly Shares OutstandingKPTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
KPTI Yearly Total Debt VS Total AssetsKPTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -19.01, we must say that KPTI is in the distress zone and has some risk of bankruptcy.
KPTI has a worse Altman-Z score (-19.01) than 84.64% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.01
ROIC/WACCN/A
WACC6.07%
KPTI Yearly LT Debt VS Equity VS FCFKPTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.33 indicates that KPTI should not have too much problems paying its short term obligations.
KPTI has a Current ratio of 1.33. This is amonst the worse of the industry: KPTI underperforms 84.46% of its industry peers.
A Quick Ratio of 1.28 indicates that KPTI should not have too much problems paying its short term obligations.
The Quick ratio of KPTI (1.28) is worse than 84.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 1.28
KPTI Yearly Current Assets VS Current LiabilitesKPTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

KPTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.90%, which is quite impressive.
KPTI shows a small growth in Revenue. In the last year, the Revenue has grown by 1.18%.
Measured over the past years, KPTI shows a very strong growth in Revenue. The Revenue has been growing by 28.85% on average per year.
EPS 1Y (TTM)57.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.29%
Revenue 1Y (TTM)1.18%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-9.39%

3.2 Future

KPTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.21% yearly.
KPTI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.35% yearly.
EPS Next Y-45.56%
EPS Next 2Y0.24%
EPS Next 3Y9.8%
EPS Next 5Y17.21%
Revenue Next Year-2.58%
Revenue Next 2Y5.3%
Revenue Next 3Y14.14%
Revenue Next 5Y24.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
KPTI Yearly Revenue VS EstimatesKPTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KPTI Yearly EPS VS EstimatesKPTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KPTI. In the last year negative earnings were reported.
Also next year KPTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPTI Price Earnings VS Forward Price EarningsKPTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPTI Per share dataKPTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.24%
EPS Next 3Y9.8%

More info and screens

0

5. Dividend

5.1 Amount

KPTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (5/30/2025, 8:10:34 PM)

After market: 4.3 +0.1 (+2.38%)

4.2

-0.33 (-7.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners49.37%
Inst Owner Change-88.65%
Ins Owners0.81%
Ins Owner Change0.82%
Market Cap36.29M
Analysts83.08
Price Target49.62 (1081.43%)
Short Float %24.71%
Short Ratio15.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.52%
Min EPS beat(2)10%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)49.33%
Min EPS beat(4)3.03%
Max EPS beat(4)149.25%
EPS beat(8)6
Avg EPS beat(8)25.16%
EPS beat(12)9
Avg EPS beat(12)19%
EPS beat(16)12
Avg EPS beat(16)27.48%
Revenue beat(2)0
Avg Revenue beat(2)-15.31%
Min Revenue beat(2)-16.5%
Max Revenue beat(2)-14.12%
Revenue beat(4)2
Avg Revenue beat(4)-3.51%
Min Revenue beat(4)-16.5%
Max Revenue beat(4)15.94%
Revenue beat(8)3
Avg Revenue beat(8)-3.68%
Revenue beat(12)6
Avg Revenue beat(12)-1.68%
Revenue beat(16)9
Avg Revenue beat(16)15.96%
PT rev (1m)-0.58%
PT rev (3m)980.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3737.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-1895.86%
Revenue NQ rev (1m)-4.23%
Revenue NQ rev (3m)-8.05%
Revenue NY rev (1m)-2.42%
Revenue NY rev (3m)-9.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.02
EYN/A
EPS(NY)-10
Fwd EYN/A
FCF(TTM)-14.2
FCFYN/A
OCF(TTM)-14.21
OCFYN/A
SpS16.45
BVpS-23.83
TBVpS-23.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.2%
FCFM N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
F-Score3
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.92%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 1.28
Altman-Z -19.01
F-Score3
WACC6.07%
ROIC/WACCN/A
Cap/Depr(3y)20.37%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.29%
EPS Next Y-45.56%
EPS Next 2Y0.24%
EPS Next 3Y9.8%
EPS Next 5Y17.21%
Revenue 1Y (TTM)1.18%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-9.39%
Revenue Next Year-2.58%
Revenue Next 2Y5.3%
Revenue Next 3Y14.14%
Revenue Next 5Y24.35%
EBIT growth 1Y10.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5YN/A